Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a common antibiotic shield the brain after a stroke?

NCT ID NCT05487417

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether the antibiotic minocycline can reduce brain injury in people with acute ischemic stroke who undergo mechanical thrombectomy (clot removal). Minocycline may protect the blood-brain barrier and limit damage from restored blood flow. The study enrolls adults aged 18–85 with large-vessel anterior circulation stroke and measures changes in infarct volume and functional recovery at three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
the antibiotic minocycline
What this could lead to
If it works, minocycline could become a simple, widely available add-on treatment to reduce brain damage and improve outcomes after stroke thrombectomy.
What could go wrong
This is a mid-stage trial with 189 participants, so results may not apply to all stroke patients. Minocycline can cause side effects like dizziness, nausea, and antibiotic-related risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

189 people

The number who actually took part.

Started

Nov 2022

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with acute cerebral infarction of anterior circulation accompanied by large vessel occlusion; 2. Age 18-85 years old; 3. The time of onset ≤ 6 hours or ≤ 24 hours suitable for mechanical thrombectomy determined by multimodal imaging; 4. The time of onset 6-24 hours, DWI shows an infarct volume less than 1/3 of the MCA blood supply area; the time of onset ≤ 6 hours, the ASPECTS(Alberta Stroke Program Early CT Score) is ≥6; 5. Preoperative NIHSS score ranges from 6 to 30 points; 6. Sign the informed consent form; Exclusion Criteria: 1. There are contraindications for mechanical thrombectomy; 2. No revascularization therapy was performed during the operation or the TICI score after revascularization therapy was less than 2b; 3. There are other major central nervous system diseases, such as brain injury, brain tumor, multiple sclerosis, etc; 4. There is evidence that the patient has bacterial endocarditis, aortic dissection, arteritis or venous cerebral infarction; 5. Renal insufficiency or hepatic insufficiency (serum creatinine \>2.0 mg/dL or 180 µmol/L; liver function greater than 3 times the normal value); 6. Known history of congestive heart failure (requiring dietary or medication changes or hospitalization) within 6 months, or myocardial infarction within 6 months; 7. There is evidence of any other life-threatening or severe diseases that may hinder the completion of the 3-month follow-up and affect the evaluation of the results; 8. Pre-existing neurological deficits or history of dementia; 9. There are infectious diseases that require antibiotic treatment before the disease; 10. Allergic to tetracyclines or unable to take minocycline for other reasons; 11. Minocycline could not be given within 1 hour after recanalization; 12. Pregnant patients; 13. Participated in another clinical trial within 30 days before inclusion in the study. 14. Refuse to sign the informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute anterior circulation ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xijing Hospital

    Xi'an, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.